InterMune Drops After Company Says Not in Talks on Sale
This article is for subscribers only.
InterMune Inc., the maker of a drug for a rare lung disease, fell in Nasdaq trading after the company said it isn’t in talks about selling itself.
The shares dropped $3.03, or 6.3 percent, to $45.45 at 4 p.m. New York time in Nasdaq Stock Market composite trading. Shares of the Brisbane, California-based company have risen 25 percent this year, including a 5 percent gain yesterday after reports InterMune was exploring a sale.